University of Baghdad Launches Ivermectin Clinical Trial for COVID-19 Patients

University of Baghdad Launches Ivermectin Clinical Trial for COVID-19 Patients

The valley where the Tigris and Euphrates Rivers flows down through what is now modern-day Iraq is literally a cradle of Civilization. After all, the world’s first writing occurs here in the form of cuneiform—the language of ancient Mesopotamia. Iraq’s University of Baghdad is the Arab’s world’s second largest university, and by some accounts got it’s start in 1067 AD as Abu-Haneefa. Regardless, its modern form materialized as the College of Law in 1908, and a College of Medicine launched in 1927. In 2020, the university was listed in the Times Higher Education World University Rankings. Recently the College of Medicine’s research arm launched a clinical trial to assess the safety and efficacy of adjuvant use of Ivermectin in Covid-19 patients with Pneumonia.

Is there something to this Ivermectin and COVID-19?

TrialSite News has been monitoring the use of Ivermectin around the globe—starting with the University of Monash findings in a laboratory cell culture experiment. Then MedinCell, a French biotech company, commenced an Ivermectin research program centering on COVID-19; in parallel, a physician in Broward County Florida received official approval from a local health board to use an Ivermectin combination therapy. Down in South America, a Brazilian University studies the use of Ivermectin on COVID-19 patients, then skipping over the Atlantic Ocean to Northern Africa Egypt where University of Tanta conducts three studies on Ivermectin. Now the University of Baghdad.

The University of Baghdad Study?

This influential Middle East institution of higher learning is comparing in this Phase I study the efficacy and safety of adjuvant use of Ivermectin in COVID-19 patients with pneumonia using Ivermectin 0.2 mg/kg (12 mg adult dose) single dose at once repeated after 1 week combined with hydroxychloroquine 400 mg daily compared to Hydroxychloroquine, plus placebo single one dose repeated after 1 week. They will enroll 50 participants.

Put another way, they want to see if adding Ivermectin to Hydroxychloroquine makes a difference to those infected with COVID-19. The study started April 18, 2020 and runs through until August 2020.

The study’s primary outcome involves the investigators looking at number of cured patients in two weeks and involves the number of patients cured as assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID-19 (PCR) in addition to chest x-rays. They are looking at secondary outcome measures including number of participants with treatment-related adverse events within the first two weeks.

Lead Research/Investigator

Faiq I Gorial, Professor

Award I Rasheed, Arab Board for Health Specialization in Iraq.

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.

    1. Dear James,

      Thanks for visiting TrialSite News.

      We have sent the principal investigator a few questions including yours–and if we can connect with him we will surely get his rational. We have seen used in a couple other instances the use of both Ivermectin and Hydroxychloroquine.

      We include a recent published document out of an Italian university (University of Naples Federico II) discussing the use of both. They hypothesize that HCQ and ivermectin may show a consequential and synergistic action if administered simultaneously both for chemoprophylaxis (prevent the disease) and treatment of COVID-19.

      https://www.jaad.org/article/S0190-9622(20)30557-0/fulltext

  1. Ivermectin is a game changer! Dr Jean Rajter in Florida is already using it and says it really helped his patients.

  2. This study titled “Usefulness of Ivermectin in COVID-19 Illness” by Amit N. Patel MD, MS. was released on April 19th 2020. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524

    However, there has been almost no media coverage of it or any further developments now for over 3 weeks. While the study is only a retrospective observational study it seems well designed. Here were my main takeaways (from a layman’s perspective):

    It was a retrospective study from 169 hospitals around the world. They reviewed over 68000 patients to select 1408 propensity matched patients. They divided them into two arms (704 each). The first was Ivermectin treatment group and the second was a control group with standard treatment (no Ivermectin). The main measured outcome was death. The result was the non-Ivermectin group had a 600% higher chance of death than the Ivermectin group. These results show a much higher efficacy than any other treatment that I’ve seen to date, including Remdesivir.

    Here are some additional notes about the trial that make the results even more impressive, IMHO:

    1. Ivermectin was dosed at only 150mcg/kg which is only 37.5% of the already proven safe dosing for other conditions.
    2. The Ivermectin group had more patients with CVD which is one of the highest risk factors with Covid-19 that leads to bad outcomes.
    3. The Ivermectin group had more severe disease at the start of the treatment as noted by the index of illness severity (qSOFA).
    4. The Ivermectin group had a larger percentage of black patients who statistically have shown worse outcomes with Covid-19.
    5. Ivermectin only costs .12 cents per patient (International wholesale price) versus the new standard of care, Remdesivir, which must be administered in a hospital at $5000/dose.
    6. Ivermectin can easily be prescribed outpatient via telemedicine to start the treatment early when it will be most effective. This is in contrast to Remdesivir which must be inpatient. The average time a patient presents at a hospital is 8days after onset of symptoms. As everyone knows, antivirals need to be administered as early as possible to inhibit the viral replication i.e. Tamiflu. The inpatient IV administration of Remdesivir makes this logistically impossible.

    Here is an excellent video that covers the Ivermectin study above and the mechanism of action: https://youtu.be/8Z1Oc4_99sk

  3. Fight against COVID19

    To fight against COVID19 India has to chalk out her own plan; we should not ape other nations. There would be serious socio-economic disaster in India if we continue total or partial lockdown. Most of the COVID19 infected patients in India are asymptomatic; and this might be due to presence of Curcumin in our daily food. So, it is very difficult to determine patient- load in India; we can not test for COVID19 in all persons under the Sun.

    Asymptomatic persons would refuse testing and any form of treatment – they would roam freely in society; and would infect the population at large; and this will in near future usher in HERD IMMUNITY in India. Most of the symptomatic patients present with mild to moderate illness; we should treat them as OPD patients. We have to treat these patients with mild-to-moderate Flu-like symptoms as quickly as possible; so that, they do not become severely ill to overwhelm the scarce indoor facilities in our country. Here is a safe outdoor treatment plan that will show quick and effective response in symptomatic patients (for adults): – Vitamin D & C and Zinc daily in usual recommend doses + Virostatic drug Ivermectin 12mg daily for 3 to 5 days + Senolytic antibiotic Azithromycin 250mg to 500mg daily for 5 days to 10 days. This treatment plan ushers in prompt response. Serious indoor patients would get these medicines + necessary supportive measures + Hydroxychloroquine (HCQS). – Arun Kumar Laha 29, Abinash Banerjee Lane. Howrah 711104. ([email protected])

    Disclaimer: –

    This is not a prescription for general public to self- medicate themselves. It is for medical fraternity to think about my humble suggestion.

    To solve the problems of COVID 19, lockdown is not the only way out; we have to rely on development of HERD IMMUNITY by exposing people to low grade infection with COVID19 and we have to treat the symptomatic patients as fast as possible, to cut short the number of serious patients requiring indoor treatment.

    Many health- care personnel and other fighters against COVID19 are losing their lives to save the humanity at large; ICMR should think about prescribing IVERMECTIN (12mg in empty stomach once in a week instead of Hydroxychloroquine) to these persons. Ivermectin is safer than Hydroxychloroquine.